Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2

Conditions

Renal Anemia 1Anemia 1

Interventions

Paclitaxel 491Carboplatin 436Gemcitabine 394Docetaxel 386Cisplatin 361pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 222Dexamethasone 213Fluorouracil 212Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 161Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 140Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × continuous erythropoietin receptor activator × Clear all
NCT00717366 2017-09-08

Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis

Hoffmann-La Roche

Phase 2 Completed
64 enrolled 15 charts 1 FDA
Classical hematology

Renal Anemia

NCT00327535 2016-08-11

A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Hoffmann-La Roche

Phase 2 Completed
153 enrolled
Classical hematology

Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡